- Trials with a EudraCT protocol (18)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (117)
18 result(s) found for: Rib.
Displaying page 1 of 1.
EudraCT Number: 2018-001657-27 | Sponsor Protocol Number: -- | Start Date*: 2018-10-03 |
Sponsor Name: | ||
Full Title: Comparison of ultrasound guided Serratus Anterior Plane Block (SAPB) with continuous local anesthetic infusion and epidural analgesia in the treatment of multiple rib fracture analgesia: a prospect... | ||
Medical condition: Multiple traumatic rib fractures | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-002691-15 | Sponsor Protocol Number: Jointcare/Fe/1/DK | Start Date*: 2006-02-16 |
Sponsor Name:Ferrosan A/S | ||
Full Title: Ginger, ginger-avokado-soy, glucosamine sulfate and ginger-ibuprofen in relation to chronic low back pain - a randomised double-blind, placebo-controlled clinical trial with parallel groups for 3 m... | ||
Medical condition: Chronic low back pain | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001767-71 | Sponsor Protocol Number: RX-3341-302 | Start Date*: 2013-06-20 | |||||||||||
Sponsor Name:Melinta Therapeutics, Inc | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DELAFLOXACIN COMPARED WITH VANCOMYCIN + AZTREONAM IN PATIENTS WITH ACUTE BACTERIAL S... | |||||||||||||
Medical condition: ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LV (Completed) ES (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003275-19 | Sponsor Protocol Number: 402-C-322 | Start Date*: 2013-01-29 | |||||||||||
Sponsor Name:Pacira Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block with Liposome Bupivacaine in Subjects Undergo... | |||||||||||||
Medical condition: Intercostal Nerve Block for Posterolateral Thoracotomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001462-42 | Sponsor Protocol Number: Pelle-926-301 | Start Date*: 2019-01-22 | |||||||||||
Sponsor Name:PellePharm, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cel... | |||||||||||||
Medical condition: Basal Cell Nevus Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) NL (Completed) DE (Completed) DK (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023819-34 | Sponsor Protocol Number: CLDE225B2209 | Start Date*: 2011-04-14 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Phase II, double-blind, randomized, Proof-of-Concept, dose-ranging trial evaluating the efficacy, safety and pharmacokinetics of oral LDE225 in treatment of adult patients with Nevoid Basal Cell ... | |||||||||||||
Medical condition: Nevoid Basal Cell carcinoma syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003764-27 | Sponsor Protocol Number: HS-20-677 | Start Date*: 2022-09-20 |
Sponsor Name:Camurus AB | ||
Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease | ||
Medical condition: Polycystic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004274-15 | Sponsor Protocol Number: Pelle-926-201 | Start Date*: 2016-02-22 | |||||||||||
Sponsor Name:PellePharm, Inc. | |||||||||||||
Full Title: Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndr... | |||||||||||||
Medical condition: Basal Cell Nevus Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001832-21 | Sponsor Protocol Number: MK-3475-671 | Start Date*: 2018-02-28 | |||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||||||||||||
Full Title: A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resecta... | |||||||||||||||||||||||
Medical condition: Neoadjuvant/Adjuvant treatment for participants with Resectable Stage II or IIIA-B (N2) NSCLC | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) LT (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004602-17 | Sponsor Protocol Number: 031-201-00186 | Start Date*: 2018-03-12 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical | |||||||||||||
Full Title: A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo... | |||||||||||||
Medical condition: Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000697-22 | Sponsor Protocol Number: FGCL-3019-095 | Start Date*: 2020-11-02 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF). | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015982-29 | Sponsor Protocol Number: UMCU-Vasc-14A | Start Date*: 2010-07-27 | ||||||||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | ||||||||||||||||||||||||||||
Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study the effects of aliskiren, hydrochlorothiazide and moxonidine on endothelial dysfunction in obesity related hyper... | ||||||||||||||||||||||||||||
Medical condition: Hypertension in subjects with abdominal obesity and the metabolic syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-005096-27 | Sponsor Protocol Number: MBPS205 | Start Date*: 2017-06-23 | |||||||||||
Sponsor Name:Mereo BioPharma 3 Ltd. | |||||||||||||
Full Title: A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, incorporating an open label substudy, in Adult Patients with Type I, III or IV Osteogenesis Imperfecta Treated with setrusu... | |||||||||||||
Medical condition: Osteogenesis imperfecta | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002693-66 | Sponsor Protocol Number: 0822-018 | Start Date*: 2007-11-13 | |||||||||||
Sponsor Name:MERCK SHARP & DOHME CORP. | |||||||||||||
Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an... | |||||||||||||
Medical condition: Postmenopausal Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Female | ||||||||||||
Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000253-27 | Sponsor Protocol Number: Pelle-926-301E | Start Date*: 2020-06-05 | |||||||||||
Sponsor Name:PellePharm, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-Label Extension Study of Patidegib Topical Gel, 2% in Subjects with Gorlin Syndrome (Basal Cell Nevus Syndrome) | |||||||||||||
Medical condition: Basal cell carcinomas (BCCs) in patients with Gorlin syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004782-41 | Sponsor Protocol Number: MO18660 | Start Date*: 2006-08-16 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in curre... | ||
Medical condition: Patients with advanced NSCLC not previously treated with chemotherapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000311-34 | Sponsor Protocol Number: P07642 | Start Date*: 2011-11-29 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effect of Golimumab Administered Subcutaneously in Subjects with Active Axial Spondyloarthritis (Phase 3b, Protocol No. P0... | |||||||||||||
Medical condition: Active Axial Spondyloarthritis (SpA) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FI (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023772-71 | Sponsor Protocol Number: C16006 | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc | |||||||||||||
Full Title: An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Predni... | |||||||||||||
Medical condition: mieloma múltiple de nuevo diagnóstico | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) GB (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
